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The prevalence of chronic kidney disease (CKD) is increasing worldwide, and 
forecasts for 2030 indicate that the number of patients requiring renal replacement 
therapies will more than double (1). The increase in requirement of renal 
replacement therapies and the availability of only few proven effective therapies 
highlight the need to develop new drugs and intervention strategies. To develop new 
drug interventions, regulatory authorities (i.e. Food and Drug Administration, 
European Medicine Agency) require that the demonstrated benefits outweigh risks. 
To this end, new drugs have to show a beneficial effect in well-designed clinical trials 
on accepted clinically meaningful endpoints, and these benefits must offset any 
adverse effects the patient may experience during the use of the drug. In trials of 
CKD progression, end-stage renal disease (ESRD) is an accepted, clinically 
meaningful endpoint because it is accompanied by a large disease burden and 
shortened survival. However, since progression to ESRD may take decades, large 
and complex clinical trials are needed to demonstrate drug efficacy (2-4). This 
results in large financial and human investments to test new drugs for patients with 
CKD. The increasing size of clinical trials and related investments in combination 
with high drug attrition rates in late phase clinical trials has fostered exploration of 
alternative approaches to test the efficacy and safety of new drugs (5-7). 
One intuitive alternative is replacing clinically meaningful endpoints by 
surrogate endpoints. A surrogate endpoint is an intermediate outcome, usually a 
laboratory measurement of a relevant risk marker, which substitutes the clinically 
meaningful endpoint (8). An example of an accepted surrogate endpoint in trials of 
CKD progression is doubling of serum creatinine, equivalent to a halving of kidney 
function. However, doubling of serum creatinine is still a late event in progression of 
kidney disease and therefore trials still require large sample sizes and long duration 
of follow-up to determine drug efficacy. Therefore, there is interest in exploring 
alternative surrogate endpoints that can be ascertained earlier in the course of renal 
disease, leading to shorter durations of follow-up in clinical trials. 
Examples of such surrogates are lesser declines than a halving in estimated 
glomerular filtration rate (eGFR), transition in eGFR classes, or changes in 





the best index of overall kidney function. eGFR decline is a necessary intermediate 
on the pathway of ESRD and it is therefore not surprising that various studies 
showed a strong and graded association between small reductions in eGFR and risk 
of developing ESRD. Based on the strong mathematical and biological association 
between eGFR and ESRD, lesser declines than a halving of GFR have received 
ample attention as potential surrogate endpoint in a series of meta-analyses of 
observational studies and clinical trials (9-14). As an alternative to GFR, albuminuria 
is proposed as a surrogate endpoint (15). The difference with eGFR, which is a 
direct marker of kidney function, is that albuminuria, just like blood pressure, is not 
only a marker of kidney damage but also causally implicated in renal disease 
progression (15,16). Treatment with angiotensin converting enzyme inhibitors (ACEi) 
or angiotensin receptor blockers (ARB) decreases albuminuria and confers 
renoprotection. Post-hoc analyses from clinical trials repeatedly showed that the 
initial reduction in albuminuria with ACEi or ARB is the driving parameter for 
renoprotection (17-19). Emerging clinical trial data show that ACEi or ARBs are not 
the only drugs that decrease albuminuria and slow the progression of CKD. First, a 
randomized clinical trial showed that pentoxifylline, a xanthine derivative registered 
for treatment of peripheral vascular disease, decreases albuminuria in patients with 
diabetes and nephropathy and slows the progression of renal function decline 
relative to placebo (20). In addition, the recent PLANET trials reported that 
atorvastatin, but not rosuvastatin, decreased proteinuria after 14 weeks treatment 
(21). 
However, developing novel surrogate endpoints based on a single renal risk 
marker such as eGFR decline or albuminuria may not be optimal. In the current drug 
development and registration process a single renal risk marker is selected and a 
drug is targeted towards that risk marker. However, there are multiple causes of 
renal disease that may not all be captured by a single risk marker alone, and drugs 
have multiple effects beyond the target risk marker (so-called off-target effects). 
These additional drug effects may also influence the ultimate renal endpoint; they 
either contribute to or counteract the on-target risk marker effect. For example, in 
addition to blood pressure lowering, RAS intervention also lowers albuminuria which 
contributes to the renal protective effect. However, these drugs also increase serum 
potassium, which is associated with increased renal risk. Hence, the rise in serum 




albuminuria reduction) (22,23). Several recent clinical trials showed no benefit on 
clinically meaningful outcomes despite the drug exerting beneficial effects on the on-
target parameter (4,24-28). In these cases off-target drug effects may confound the 
relationship between a single risk marker or surrogate and renal outcome. This 
suggests that a score that integrates all known drug-induced effects is potentially 
more accurate in predicting the ultimate drug effect than using a single risk marker 
alone (29). 
Using such multiple risk parameter scores to establish drug efficacy in clinical 
trials is not much different from the risk prediction scores that are used to establish a 
patient's renal risk. When we aim to predict the risk of an individual we accept that 
multiple risk markers are of relevance to the clinical outcome, and thus risk 
prediction scores are developed consisting of multiple risk markers. In drug 
development a single risk marker is selected as target for therapy. However, nearly 
all drugs have effects on multiple risk markers. Therefore it seems logical to integrate 
these multiple drug effects to better predict the ultimate drug effect. Recently, a 
score was developed that integrates multiple short-term drug effects in order to 
predict the long-term drug effect on renal and cardiovascular outcomes. This so-
called PRE score was used to establish the effect of the angiotensin receptor 
blockers losartan and irbesartan in patients with type 2 diabetes. Interestingly, the 
ARBs significantly changed 7 out of 11 measured renal risk markers. Integrating all 
risk markers in a PRE score showed that it provided a better prediction of the drug 
effect on hard renal outcomes than any change in single markers (30,31). External 
validation studies confirmed these results (32). Therefore, such scores may be better 
suited as surrogate endpoint in clinical trials than using a single marker alone. 
Although using changes in multiple parameters to establish drug efficacy is 
intuitively appealing, the approach is still in its infancy and requires more prospective 
validation. In particular, the validity of the multiple parameter drug response score 
has been ascertained for drugs intervening in the RAS but it is unclear whether the 
score will be equally valid for other drugs. Especially whether the score can be used 
for novel drugs targeting for example inflammatory pathways requires further 
investigation. Moreover, the risk markers currently included in the score are limited to 
what is measured and recorded in the trials: physical measurements and standard 
biochemical measurements. Novel risk markers may be identified and integrated to 





Another concern is that recent clinical drug trials in type 2 diabetes were 
terminated early for safety reasons, due to an increase in hospitalization due to heart 
failure in the active treatment arm. This was the case for the Nrf2 activator 
bardoxolone methyl, the endothelin antagonist avosentan and the peroxisome 
proliferator-activated receptor activator rosiglitazone (24,33,34). These drug failures 
illustrate that the validity of the score needs to be ascertained for other outcomes 
than ESRD, in order to provide a more complete profile of the benefit-risk profile of a 
given drug. 
 
Scope of the thesis 
 
Better prediction of drug effects on clinical outcomes may be achieved by risk scores 
that integrate the effect on multiple risk markers, instead of using single markers 
alone. Such an approach, with the so-called PRE score, was previously used for 
drugs intervening in the RAS, but before it can be implemented in practice more 
validation is required. In this thesis we determined whether this multiple parameter 
drug response score could also be used for other drug classes that are used to treat 
patients with type 2 diabetes. In addition, we aimed to address both safety and 
efficacy by predicting ESRD and heart failure outcomes. Another important aspect is 
that drug effects are frequently assessed on a group level, but whether the response 
in multiple risk markers in response to therapy can improve prediction of who is likely 
to benefit from treatment is not yet known. And lastly, a multiple parameter drug 
response score such as proposed in this thesis needs to be accepted by all 
stakeholders in drug development. This includes academics, the pharmaceutical 
industry and regulatory authorities, and their willingness to accept such a score 
needs to be ascertained. 
In Chapter 2 we investigated whether early intervention with drugs that 
intervene in the RAS is more beneficial in delaying ESRD in patients with type 2 
diabetes than intervention in later stages of the disease. Because ESRD can take 
decades to manifest, prospective clinical trial data is not available to answer this 
question. Therefore we built a model with patient data from completed clinical trials 
in nephrology from all stages of CKD. The model is based on disease stages defined 






Figure 1. Schematic representation of the PRE score. In step A the associations between multiple 
risk markers (e.g. blood pressure, albuminuria) and clinical outcomes (e.g. ESRD) are established. In 
step B these associations are applied to the baseline and follow-up risk marker measurements in 
each patient. The PRE score then predicts the individual risk change of clinical outcomes induced by 
treatment. 
 
In Chapter 3 we performed a post-hoc analysis of the AleCardio trial in which 
patients with type 2 diabetes were treated with the dual PPAR agonist aleglitazar. 
The trial was stopped early due to futility and an increase in hospitalization due to 
heart failure in the treatment arm. Our aim was to predict whether the adverse heart 
failure outcomes could have been prevented by more stringent baseline inclusion 
criteria by using individual or multiple risk markers for heart failure. Secondly, we 
investigated whether the observed heart failure risk could have been predicted 
based on short-term response in individual risk markers, or a composite consisting of 
multiple risk markers. In Chapter 4 we applied the multiple parameter drug response 





predict the outcome of an ongoing phase III trial on the endpoints ESRD and 
hospitalization due to heart failure. In Chapter 5 we applied the multiple parameter 
drug response score on individual patients that were subjected to drugs that 
intervene in the RAS. We determined whether integrating the effect on multiple risk 
markers in response to RAS intervention would improve the prediction of who will 
benefit from treatment, compared to using single risk markers alone. In Chapter 6 
we performed a questionnaire to investigate whether stakeholders in drug 
development would be willing to accept novel surrogate endpoints, and whether they 
deemed surrogate endpoints based on multiple risk markers more accurate than 
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